CSF1R and giant cell tumor: Clinically available drugs targeting CSF1 or CSF1R include pexidartinib, which repolarizes M2 macrophages [54] and has demonstrated safety and activity in a phase 3 trial [55] resulting in the first available systemic therapy available for tenosynovial giant cell tumors.